Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.
Talia M, Cirillo F, Spinelli A, Zicarelli A, Scordamaglia D, Muglia L, De Rosis S, Rigiracciolo DC, Filippelli G, Perrotta ID, Davoli M, De Rosa R, Macirella R, Brunelli E, Miglietta AM, Nardo B, Tosoni D, Pece S, De Francesco EM, Belfiore A, Maggiolini M, Lappano R. Talia M, et al. Among authors: filippelli g. J Exp Clin Cancer Res. 2023 Jul 12;42(1):164. doi: 10.1186/s13046-023-02747-5. J Exp Clin Cancer Res. 2023. PMID: 37434266 Free PMC article.
The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells.
Santolla MF, Talia M, Cirillo F, Scordamaglia D, De Rosis S, Spinelli A, Miglietta AM, Nardo B, Filippelli G, De Francesco EM, Belfiore A, Lappano R, Maggiolini M. Santolla MF, et al. Among authors: filippelli g. Cells. 2022 Aug 4;11(15):2402. doi: 10.3390/cells11152402. Cells. 2022. PMID: 35954247 Free PMC article.
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.
Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, Botti C, Vizza E, Carpino A, Pizzuti L, Latorre A, Giannarelli D, Lopez M, Di Lauro L. Vici P, et al. Among authors: filippelli g. J Exp Clin Cancer Res. 2011 Apr 12;30(1):39. doi: 10.1186/1756-9966-30-39. J Exp Clin Cancer Res. 2011. PMID: 21481280 Free PMC article. Clinical Trial.
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Colucci G, Maiello E, Gebbia V, Giuliani F, Serravezza G, Lelli G, Leo S, Filippelli G, Nicolella G, Brandi M. Colucci G, et al. Among authors: filippelli g. Cancer. 1999 Feb 1;85(3):535-45. Cancer. 1999. PMID: 10091727 Clinical Trial.
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Lutrino ES, Orlando L, Febbraro A, Giampaglia M, Zamagni C, Schiavone P, Scavelli C, Dima G, Fedele P, Giordano G, Bilancia D, Quaranta AM, Rubino D, Filippelli G, Fontanella C, Caliolo C, Marino A, Calvani N, Ferrara P, Cinieri S. Lutrino ES, et al. Among authors: filippelli g. Tumori. 2020 Aug;106(4):301-305. doi: 10.1177/0300891619887225. Epub 2019 Dec 18. Tumori. 2020. PMID: 31847742 Free PMC article.
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
Palmeri S, Meli M, Danova M, Bernardo G, Leonardi V, Dastoli G, Rausa L, Russo A, Filippelli G, Palmieri G, Russo A, Della Vittoria Scarpati M, Lo Russo V, Di Lauro L, Colucci G, Bruni G, Piazzi M, Gebbia N, Spada S. Palmeri S, et al. Among authors: filippelli g. J Cancer Res Clin Oncol. 1998;124(3-4):191-8. doi: 10.1007/s004320050154. J Cancer Res Clin Oncol. 1998. PMID: 9619746 Clinical Trial.
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: filippelli g. Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12. Breast. 2018. PMID: 30092500
Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients.
Marech I, Ammendola M, Sacco R, Sammarco G, Zuccalà V, Zizzo N, Leporini C, Luposella M, Patruno R, Filippelli G, Russo E, Porcelli M, Gadaleta CD, De Sarro G, Ranieri G. Marech I, et al. Among authors: filippelli g. J Cell Mol Med. 2016 Jul;20(7):1373-80. doi: 10.1111/jcmm.12826. Epub 2016 Apr 22. J Cell Mol Med. 2016. PMID: 27105577 Free PMC article.
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Orlando L, Giotta F, Lorusso V, De Vita F, Filippelli G, Maiello E, Riccardi F, Pappagallo GL, Fedele P, Gebbia N, Verderame F, Barni S, Blasi L, Pisconti S, Colucci G, Cinieri S. Orlando L, et al. Among authors: filippelli g. Future Oncol. 2014 Apr;10(5):725-33. doi: 10.2217/fon.13.186. Future Oncol. 2014. PMID: 24799054 Clinical Trial.
Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review.
Leporini C, Saullo F, Filippelli G, Sorrentino A, Lucia M, Perri G, Gattuta GL, Infusino S, Toscano R, Dima G, Olivito V, Paletta L, Bottoni U, De Sarro G. Leporini C, et al. Among authors: filippelli g. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S78-85. doi: 10.4103/0976-500X.120966. J Pharmacol Pharmacother. 2013. PMID: 24347989 Free PMC article.
92 results